International Journal of Radiation Oncology*Biology*Physics
Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study
References (34)
- et al.
Late effects of radiation therapy on the gastrointestinal tract
Int. J. Radiat. Oncol. Biol. Phys.
(1995) - et al.
Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment
Int. J. Radiat. Oncol. Biol. Phys.
(1995) Optimizing the radiation treatment and outcome of prostate cancer
Int. J. Radiat. Oncol. Biol. Phys.
(1985)- et al.
Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation
J. Urol.
(1995) - et al.
Dose response observations for local control of adenocarcinoma of the prostate
Int. J. Radiat. Oncol. Biol. Phys.
(1985) - et al.
Factors influencing incidence of acute Grade 2 morbidity in conformal and standard radiation treatment of prostate cancer
Int. J. Radiat. Oncol. Biol. Phys.
(1995) - et al.
Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect
Int. J. Radiat. Oncol. Biol. Phys.
(1996) Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase 1 dose-escalation study
Int. J. Radiat. Oncol. Biol. Phys.
(1994)Three-dimensional conformal radiation therapy: A testable hypothesis
Int. J. Radiat. Oncol. Biol. Phys.
(1991)- et al.
National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Commission on Cancer
J. Urol.
(1994)
3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients
Int. J. Radiat. Oncol. Biol. Phys.
Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy
Radiother. Oncol.
Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome
Urol
Early observations of acute and chronic toxicity and PSA response in patients with carcinoma of the prostate treated on a dose escalation study with 3D-CRT
Int. J. Radiat. Oncol. Biol. Phys.
Cancer statistics, 1994
CA Cancer J. Clin.
Results of conservative management of clinically localized prostate cancer
N. Engl. J. Med.
Patterns of failure analysis of patients with high pretreatment PSA treated by radiation therapy: The need for improved systemic and loco-regional treatment
J. Clin. Oncol.
Cited by (156)
Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Changing trends in the patterns of care process survey
2011, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :US PCS results indicate that many prostate cancer patients have been routinely treated with total doses of >70 Gy in the United States (25, 28). The use of increasing radiation doses in Japan might reflect the widespread dissemination of clinical trial results (32–35) and also a growing acceptance by radiation oncologists and urologists that radical EBRT is effective for treating prostate cancer (30, 31). Results of the current study indicate that hormone therapy was commonly used in conjunction with radiotherapy during the survey period in Japan.
Stereotactic Body Radiotherapy for Primary Management of Early-Stage, Low- to Intermediate-Risk Prostate Cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee
2010, International Journal of Radiation Oncology Biology PhysicsGenitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose-Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity
2009, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Because a dose–response relationship has been shown for prostate cancer, particularly in patients with intermediate-risk prostate cancer (1, 2), dose escalation trials have been performed for localized prostate cancer, and improved local control has been reported (3, 4).
Combined Hypofractionated Radiation and Hormone Therapy for the Treatment of Intermediate-Risk Prostate Cancer
2008, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :There is a supposition that conventional doses of radiation (70.2–72 Gy in 1.8- to 2-Gy fractions) may be inadequate and that further treatments may be required (22). Some have proposed dose escalation to 76–78 Gy as a solution (23–25), whereas others prefer the use of standard radiation doses with the adjunct of hormone therapy. Androgen ablation causes tumor regression by inhibiting DNA synthesis and proliferation of androgen-dependent cancer cells (26).
Tomotherapy for prostate adenocarcinoma: A report on acute toxicity
2007, Radiotherapy and Oncology
- 1
Present address of B. E. Epstein: Vanderbilt Hospital, Nashville, TN